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The metabolism of the amino acid L-tryptophan is a highly regulated
physiological process leading to the generation of several neuroactive
compounds within the central nervous system. These include the aminergic
neurotransmitter serotonin (5-hydroxytryptamine, 5-HT), products of the
kynurenine pathway of tryptophan metabolism (including 3-hydroxykynurenine,
3-hydroxyanthranilic acid, quinolinic acid and kynurenic acid), the
neurohormone melatonin, several neuroactive kynuramine metabolites of
melatonin, and the trace amine tryptamine. The integral role of central
serotonergic systems in the modulation of physiology and behaviour has been
well documented since the first description of serotonergic neurons in the
brain some 40 years ago. However, while the significance of the peripheral
kynurenine pathway of tryptophan metabolism has also been recognised for
several decades, it has only recently been appreciated that the synthesis of
kynurenines within the central nervous system has important consequences
for physiology and behaviour. Altered kynurenine metabolism has been
implicated in the pathophysiology of conditions such as acquired
immunodeficiency syndrome (AIDS)-related dementia, Huntington’s disease
and Alzheimer’s disease. In this review we discuss the molecular mechanisms
involved in regulating the metabolism of tryptophan and consider the medical
implications associated with dysregulation of both serotonergic and
kynurenine pathways of tryptophan metabolism.
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The essential amino acid L-tryptophan
(tryptophan) is ingested as part of the diet and
is required by every living cell in order to
synthesise protein. Metabolism of tryptophan
yields several biologically active molecules,
including many important neuromodulators
of central nervous system (CNS) function.
The mechanisms involved in regulating
tryptophan metabolism within the CNS, as well
as the medical implications resulting from
dysregulation of these mechanisms, are
discussed in this review.
Regulation of plasma free tryptophan
concentrations
Tryptophan is the only amino acid to bind
plasma albumin and exists in an equilibrium
between albumin-bound and free forms in the
peripheral circulation (Ref. 1). At rest, about
90% of total plasma tryptophan is bound to
albumin, forming a complex that cannot cross
the blood–brain barrier (BBB); the remainder
circulates in a free form that is available for
transport across the BBB into the brain (Ref. 2).
A major determinant of the ratio of free
tryptophan to albumin-bound tryptophan is the
plasma concentration of non-esterified fatty
acids (NEFAs), which also bind to albumin and
by doing so displace tryptophan from its
binding site (Ref. 3), resulting in an elevation
of free tryptophan in the plasma (Refs 4, 5).
Increases in plasma NEFA concentrations
can come about under many different
circumstances, including upon activation of the
sympathetic nervous system during sustained
exercise (Ref. 6), when b-adrenoceptor-
mediated lipolysis leads to increased release of
NEFAs from adipose tissue (Ref. 7). Other
exogenous factors may also displace tryptophan
from albumin, as is the case for numerous
drugs (albeit at pharmacological doses),
including the benzodiazepines (Ref. 8) and the
lipid-lowering drug clofibrate (Ref. 9).
Until recently, it was widely argued that the
increase in the free pool of tryptophan
following NEFA elevation was the primary
determinant of the increase in brain tryptophan
concentrations in response to exercise or other
challenges; however, several recent findings
argue against this simple interpretation (Ref. 6).
While it remains a matter for debate whether
plasma concentrations of total tryptophan or
free tryptophan are most critical for
determining the rate of tryptophan uptake into
the brain (Ref. 6), there is convincing evidence
to suggest that enhanced dissociation of
tryptophan from albumin within the local
environment of the cerebral microvascular
system is an important factor (as discussed
further below) (Refs 10, 11).
Tryptophan transport across the BBB
The transport of tryptophan across the BBB and
into the extracellular fluid of the CNS plays a
critical role in the regulation of brain
tryptophan metabolism. For example, as
tryptophan hydroxylase (TPH; the rate-limiting
enzyme in the metabolism of tryptophan to
serotonin) is not saturated at baseline
concentrations of tryptophan (Refs 12, 13), the
rate of serotonin synthesis in the brain can be
either increased or decreased by altering the
rate of tryptophan transport across the BBB
(Refs 14, 15).
The activation of the sympathetic nervous
system appears to play a significant role in the
regulation of tryptophan availability to the
brain. Indeed, sympathetic nervous system
activation has been shown to contribute to the
increases in brain tryptophan concentrations
seen after stress-related and immune challenges
in experimental animals (Ref. 16). Furthermore,
animal studies have established that tryptophan
availability to the brain, but not other organs, is
increased by peripheral administration of
b-adrenoceptor agonists (Refs 17, 18, 19, 20, 21)
– specifically agonists at the b2- and
b3-adrenoceptors (Ref. 22) – and decreased by
peripheral administration of b-adrenoceptor
antagonists (Ref. 16). The mechanisms
underlying the effects of b-adrenoceptor
agonists on brain tryptophan concentrations are
not clear, but the weight of the evidence
suggests that they are independent of changes in
NEFAs (Ref. 23). Some studies have suggested
that there might be a direct stimulatory influence
of the sympathetic nervous system on the
transporter mediating tryptophan uptake into
the CNS (Refs 20, 21), a hypothesis consistent
with the observation that capillary endothelial
cells isolated from rat and human cerebral
microvessels possess b2-adrenoceptors (Ref. 24).
Tryptophan is transported from the blood
across the BBB by a competitive transport
carrier that is shared by several large neutral
amino acids (LNAAs), including the aromatic
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amino acids tyrosine and phenylalanine and the
branched-chain amino acids leucine, isoleucine
and valine, in rats (Refs 13, 25, 26) and in
humans (Ref. 27). The functional properties of
this transporter correspond to those of the
classically characterised sodium-independent
amino acid transport system L (Ref. 28).
However, the L-type amino acid transporter at
the BBB (LAT1; Fig. 1) has a much higher
affinity (lower Km) for amino acids compared
with L-type amino acid transport systems in
peripheral tissues (Ref. 29) and is expressed at
much higher levels at the BBB compared with
other tissues (Ref. 30). LAT1, which spans the
membrane 12 times, requires an additional
single-membrane-spanning protein, the heavy
chain of 4F2 cell surface antigen (4F2 heavy
chain; 4F2hc; CD98), for its functional
expression (Ref. 31). If the subcellular
expression of the BBB LAT1 is similar to that of
other amino acid transporters that have been
characterised at the BBB (Ref. 32), it is likely to
be expressed on both the luminal surface of the
endothelial cell (transporting tryptophan into
the cell) and the abluminal surface of the
endothelial cell (transporting tryptophan out
of the cell into the extracellular fluid of the
brain). This hypothesis is supported by
immunohistochemical studies (Ref. 33). Owing
to the competitive nature of amino acid
transport across the BBB by LAT1 and the low
abundance of tryptophan relative to other
LNAAs, increases in the ratio of free
tryptophan to other LNAAs (at least within the
local cerebral microvasculature) increase the
rate of tryptophan uptake into the brain. The
reverse is also true: increases in the plasma
concentrations of other LNAAs decrease the
rate of tryptophan uptake into the brain
(Ref. 34).
As mentioned above, one mechanism
involved in controlling the availability of
tryptophan for transport into the brain
appears to involve enhanced dissociation of
tryptophan from albumin within the cerebral
microvasculature (Ref. 10). This process is
dependent upon cerebral haemodynamics, with
greater dissociation rates under conditions of
low cerebral blood flow, possibly due to
increased interactions between the albumin-
bound tryptophan complex and the glycocalyx
of the endothelial cell membrane (Refs 10, 35).
These findings suggest that temporally dynamic
or spatial differences in regional cerebral blood
flow may have important consequences for
rates of tryptophan uptake within specific
regions of the CNS. Other mechanisms that
might regulate brain tryptophan concentrations
include alterations in the kinetics of tryptophan
transport across the BBB, changes in brain
protein metabolism, or changes in the rate of
tryptophan efflux from the brain (Refs 36, 37).
Tryptophan uptake into cells of the CNS
Once tryptophan has crossed the BBB into the
extracellular fluid or cerebrospinal fluid (CSF)
of the CNS, it is freely available for uptake into
cells of the CNS for utilisation in multiple
Figure 1. Overview of tryptophan metabolism in the central nervous system. (Legend; see next page for
figure.) (a) The majority of tryptophan (Trp) in the periphery (approximately 90%) is bound to plasma albumin.
As the albumin–tryptophan complex travels through the cerebrovasculature, the dissociation of tryptophan
from albumin is facilitated, possibly by interactions between the complex and the glycocalyx of the
endothelial cell membrane. This dissociation is also facilitated by a decrease in the rate of blood flow,
suggesting that changes in regional cerebral blood flow could alter the local availability of tryptophan for
uptake into the brain. (b) Free tryptophan is transported across the blood–brain barrier via the L-type amino
acid transporter (LAT1)/4f2 heavy chain complex, at the luminal and abluminal surfaces of endothelial cells.
The aromatic amino acids tryptophan, tyrosine (Tyr) and phenylalanine (Phe) compete with the branched-
chain amino acids leucine (Leu), isoleucine (Ile) and valine (Val) for transport by LAT1. (c) Once in the
extracellular fluid or cerebrospinal fluid in the brain, tryptophan is available for uptake into all cells for protein
synthesis, and specialised cells that synthesise neuroactive metabolites of tryptophan, including serotonin (in
serotonergic neurons and mast cells), tryptamine (possibly in ‘D’ neurons that express aromatic amino acid
decarboxylase), and kynurenines (in astrocytes, microglia, macrophages and dendritic cells). The molecular
mechanisms of high-affinity transport of tryptophan into cellular compartments within the central nervous
system are not known. (d) Melatonin synthesised in the pineal gland (which is not protected by the blood–
brain barrier) has ready access to the brain, where it is involved in neural signalling through G-protein-coupled
receptors, but also has antioxidant effects and can serve as a precursor for synthesis of other molecules with
antioxidant effects, including kynuramines.
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metabolic pathways (Fig. 1). The molecular
mechanisms underlying the uptake of
tryptophan into different cell types within the
CNS are virtually unknown as neither the
purification of neutral amino acid transport
systems nor the cloning of the genes coding for
these transport systems has yet been reported
(Ref. 38). It is also unknown if different cell
types within the CNS utilise different neutral
amino acid transport systems, and whether or
not different transport systems are used to
deliver tryptophan to specific intracellular
metabolic pathways (e.g. pathways for protein
synthesis versus pathways for synthesis of
serotonin in serotonergic neurons or mast
cells, kynurenines in astrocytes, microglia,
Overview of tryptophan metabolism in the central nervous system 
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Figure 1. Overview of tryptophan metabolism in the central nervous system. (See previous page
for legend.)
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Tryptophan metabolism in serotonergic neurons
Expert Reviews in Molecular Medicine C 2006 Cambridge University Press
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Figure 2. Tryptophan metabolism in serotonergic neurons. Tryptophan (Trp) in the extracellular fluid is
transported into the serotonergic neuron by a high-affinity neuronal tryptophan transporter. In the serotonergic
neuronal cell body, the rate-limiting enzyme tryptophan hydroxylase 2 (TPH2) is located in the cytoplasm and,
using molecular oxygen (O2) and the cofactor tetrahydrobiopterin (BH4) catalyses the hydroxylation of
tryptophan to 5-hydroxytryptophan (5-HTP), which is rapidly converted to 5-hydroxytryptamine (5-HT,
serotonin) by aromatic L-amino acid decarboxylase, using pyridoxal-50-phosphate (P5P) as cofactor. TPH2
activity is increased by action-potential- and Ca2þ-dependent phosphorylation, and the phosphorylated form
of TPH2 is stabilised by binding to 14-3-3 protein. Serotonin is then either: (a) metabolised by flavoprotein
monoamine oxidase B (located on the mitochondrial membrane) to 5-hydroxyindole acetaldehyde (5-HIA) and
then by aldehyde dehydrogenase to the acid metabolite 5-hydroxyindoleacetic acid (5-HIAA), which is
excreted from the cell by an energy-dependent clearance mechanism; or (b) packaged in synaptic vesicles, via
the action of vesicular monoamine transporter 2 (VMAT2), bound by the carrier protein serotonin-binding
protein (SBP), and then released into the extracellular fluid by calcium-dependent exocytosis. (c) Released
serotonin can be recycled within the cell following reuptake by the serotonin transporter (SERT) or can be
metabolised to 5-HIAA by postsynaptic cells containing monoamine oxidase. For chemical structures of key
metabolites, see Ref. 106.
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macrophages or dendritic cells, or melatonin in
pinealocytes; Fig. 1).
Serotonergic neurons
Very little is known about the mechanisms
underlying tryptophan uptake into serotonergic
neurons in the brain. Although there is good
evidence supporting the hypothesis that a
dynamic, regulatory barrier exists between
extracellular brain levels of tryptophan and
intraneuronal enzymatic pathways (Fig. 2),
the molecular identity of the neuronal
tryptophan transporter(s) in serotonergic
neurons is not known. Nevertheless, two
uptake processes with low (Km ¼ 1 " 1023 M) and
high (Km ¼ 1 " 1025 M) affinities for tryptophan
have been elucidated using synaptosomal
preparations prepared from the septum, a
region of the brain with high concentrations of
serotonin nerve endings (Ref. 39). The high-
affinity uptake system is sensitive to ion species
and concentration, pH, temperature and
uncouplers of energy metabolism, whereas the
low-affinity system does not appear to be
temperature-dependent, drug-sensitive or even
stereospecific (Refs 40, 41). The high-affinity
system has some specificity, as competition of
radiolabelled tryptophan against equimolar
amounts of unlabelled tyrosine has no effect on
tryptophan conversion to serotonin (Ref. 42).
Although tryptophan is accumulated by both
high-affinity and low-affinity systems, it has
been proposed that the high-affinity, low-
capacity uptake system may maintain
appropriate neuronal levels of tryptophan for
serotonin synthesis whereas the low-affinity,
high-capacity uptake system may subserve
general metabolic functions (Ref. 43). It should
also be emphasised that tryptophan uptake
assays do not differentiate between uptake into
serotonergic neuronal cell bodies or fibres,
where tryptophan can be converted to serotonin,
and uptake in other cellular compartments,
where it is not. Nevertheless, tryptophan
transport into brain synaptosomes is a dynamic
and regulated process that varies over the
circadian cycle (Ref. 44) and can be regulated by
a range of endogenous and pharmacological
compounds including corticosterone (Ref. 45),
hydrocortisone acetate (Ref. 45), cocaine (Ref. 39)
and parachlorophenylalanine (PCPA) (Ref. 40), a
drug that selectively lesions serotonergic
neurons.
Although we do not know which specific
tryptophan transport systems are present in
serotonergic neurons within the CNS, lesion
studies in developing rats suggest that the
uptake of tryptophan during postnatal
development is not more active in serotonergic
terminals than it is in other types of nerve
terminals (Ref. 46). However, we cannot assume
that serotonergic neurons are homogeneous in
their cellular and molecular properties (Ref. 47)
and therefore it remains possible that there are
subpopulations of serotonergic neurons with
unique tryptophan transport mechanisms.
Consistent with a meaningful heterogeneity of
tryptophan transport mechanisms within the
CNS, both the Vmax and Km of high-affinity
tryptophan transport vary across different brain
regions (Ref. 48).
Non-neuronal cells
In addition to serotonergic neurons, four
different non-neuronal cell types within the
CNS (or with access to the CNS) – including
astrocytes, infiltrating macrophages/microglia,
dendritic cells and mast cells – are able to
synthesise neuroactive metabolites using
tryptophan as a precursor. Astrocytes,
infiltrating macrophages/microglia and
dendritic cells synthesise multiple neuroactive
metabolites via the actions of the rate-limiting
synthetic enzyme indoleamine 2,3-dioxygenase
(IDO) and the kynurenine pathway of
tryptophan metabolism (Ref. 49) (Fig. 3). Mast
cells utilise tryptophan to synthesise serotonin
(Ref. 50), which may contribute to
neuroimmune interactions within the brain,
including modulation of the permeability of the
BBB (Ref. 51). The neuroactive metabolites
generated by the kynurenine pathway include
3-hydroxykynurenine and 3-hydroxyanthranilic
acid, the excitotoxic N-methyl-D-aspartate
(NMDA) receptor agonist quinolinic acid, and
the NMDA and a7 nicotinic acetylcholine
receptor antagonist kynurenic acid.
As is the case with serotonergic neurons, we
do not currently know which specific
tryptophan transport systems are present in any
of these cell types, but convincing evidence
suggests that specific transport systems exist
and that their regulation may be critical for cell
function. For example, while we do not know
the identity of tryptophan transport systems in
mast cells, it is clear that tryptophan availability
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Tryptophan metabolism in astrocytes, infiltrating macrophages, microglial cells
and dendritic cells in the central nervous system
Expert Reviews in Molecular Medicine C 2006 Cambridge University Press
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Figure 3. Tryptophan metabolism in astrocytes, infiltrating macrophages, microglial cells and dendritic
cells in the central nervous system. Tryptophan (Trp) in the extracellular fluid is transported into glial or
immune cells by a high-affinity tryptophan transporter. The rate-limiting enzyme indoleamine 2,3-dioxygenase
(IDO) catalyses the initial enzymatic step in the kynurenine pathway leading to the synthesis of a number of
neuroactive compounds, including the free-radical generators 3-hydroxykynurenine and 3-hydroxyanthranilic
acid, the excitotoxic N-methyl-D-aspartate (NMDA) receptor agonist and free-radical generator quinolinic acid,
and the neuroprotective NMDA receptor antagonist kynurenic acid. IDO is induced by interferon g, and
therefore kynurenine metabolism is increased during many inflammatory conditions involving the central
nervous system. For chemical structures of key metabolites, see Ref. 106.
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is a determinant of the proportion of serotonin,
compared with histamine, released from this
cell type (Ref. 50). It has been proposed that
tryptophan uptake, coupled to metabolism of
tryptophan, is an important factor in the
immunoregulatory functions (e.g. immune
tolerance; see below) of antigen-presenting cells
such as macrophages or dendritic cells (Ref. 52),
and a preliminary report has described a very
high-affinity (Km ¼ 230 nM) tryptophan-selective
transport system in human monocyte-derived
macrophages (Ref. 53).
Pinealocytes
Some progress has been made in identifying
transport systems mediating tryptophan uptake
in pinealocytes within the pineal gland.
Pinealocytes synthesise serotonin from
tryptophan as a precursor for synthesis of
melatonin. Melatonin is then released from the
cell and acts as a neurohormone to affect CNS
function. Unlike cells in the CNS, the pineal is
not protected by the BBB; therefore, as expected,
reductions in plasma tryptophan concentrations
can reduce melatonin synthesis and secretion
from the pineal gland (Ref. 54). Tryptophan is
transported into pinealocytes by both low- and
high-affinity transport mechanisms. Studies
using rat pineal gland have demonstrated that
high-affinity tryptophan uptake is mediated by
the aromatic amino acid transport system T
(Ref. 55) (Table 1).
ATP-binding cassette transporter G
(ABCG) family members
One candidate protein for facilitation of
tryptophan transport across the plasma
membrane in cells of the CNS is the product of
the human homologue of the Drosophila white
gene, so named because mutations in this gene
cause flies to have white eyes rather than wild-
type red eyes. In Drosophila, the white protein is
thought to facilitate the transmembrane
transport of tryptophan or a tryptophan
metabolite in the eye (Ref. 56). Human (ABCG1)
and murine (ABC8) homologues of the
Drosophila white gene have been cloned (Ref. 57)
and, together with the closely related ABCG4
gene, have been shown to be expressed in the
brain and eye (Refs 58, 59, 60, 61). Indeed,
ABCG1 is expressed in areas of the brain
associated with serotonergic function (e.g. the
dorsal raphe nucleus) and in the pineal gland
(Ref. 58). While there is presently no direct
evidence for a role for ABCG1 and ABCG4
in facilitation of tryptophan transport in
Table 1. Tryptophan uptake systems in pineal and central nervous system tissues
Uptake system Tissue Km Species Refs
LAT1 (light chain) and 4F2 heavy chain Bovine blood–brain
barrier
10–100 mM Cow 30, 199
High-affinity synaptosomal Trp transport
system
Brain synaptosomes
(septum)
10 mM Rat 39
ND Neurons (cortical
synaptosomes)
67 mM (light
phase)
Rat 44
42 mM (dark
phase)
System-L-related Trp transport system Monocyte-derived
macrophages
19 mM Human 53
High-affinity Trp transport system Monocyte-derived
macrophages
230 nM Human 53
High-affinity Trp transport system;
aromatic amino acid transport system T
Dissociated
pinealocytes
4 nM Rat 55
Abbreviations: LAT1, L-type amino acid transporter 1; ND, not determined; Trp, tryptophan.
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mammalian systems, based on arguments of
functional homology, the well-established
function of the white protein in Drosophila, and
the high expression levels of ABCG1 and
ABCG4 in macrophages (Refs 62, 63), ABCG1
and related proteins are candidate proteins for a
role in modulation of tryptophan transport or
metabolism in mammals. Intriguingly,
polymorphisms in the ABCG1 gene (Refs 57, 64,
65) have been associated with bipolar
depression and mood disorders, conditions
associated with serotonergic dysfunction.
Further studies are warranted to study the role
of this family of proteins in tryptophan
transport and metabolism in the CNS.
Summary of tryptophan uptake
In summary, preliminary reports looking at
homogeneous populations of cells (pinealocytes
and monocyte-derived macrophages) with
unique metabolic demands for tryptophan have
demonstrated the presence of high-affinity
tryptophan uptake systems with Km values in
the nanomolar range. It remains to be seen if
serotonergic neurons or subpopulations of
serotonergic neurons also have high-affinity
uptake systems associated with their unique
metabolic demands for tryptophan. Given the
diversity of tryptophan uptake mechanisms in
different cellular compartments (Table 1), it is
possible that pharmacological approaches could
be used to selectively regulate tryptophan
uptake into different cellular compartments in
order to regulate the metabolism of tryptophan
via specific metabolic pathways. This is an
exciting direction for future research, with
broad medical implications.
Serotonin biosynthesis and metabolism
Once tryptophan gains access to the cytoplasm
of mast cells or serotonergic dendrites, somata,
fibres or presynaptic nerve terminals, a number
of highly regulated enzymes and co-factors
convert tryptophan to serotonin (Fig. 2).
Evidence suggests that access of tryptophan to
serotonin-producing neurons in the brain is a
critical step in regulation of serotonin
biosynthesis (Ref. 42). Elevations in brain
tryptophan concentrations lead to increased
serotonin biosynthesis, and thus mechanisms
controlling brain tryptophan levels (see above)
contribute to the tonic regulation of serotonin
synthesis in serotonergic neurons (Refs 14, 15,
66, 67). Indeed, brain tryptophan concentrations
are positively and significantly correlated with
brain serotonin and 5-hydroxyindoleacetic acid
(5-HIAA; the major serotonin catabolite)
concentrations (Ref. 66).
Tryptophan hydroxylase
Although availability of tryptophan in the brain
is rate-limiting for the synthesis of serotonin in
serotonergic neurons, the rate-limiting enzyme
in the synthesis of serotonin is TPH (tryptophan
hydroxylase; tryptophan 5-monooxygenase; EC
1.14.16.4) (Fig. 2). Until recently, it was assumed
that TPH found in both the periphery and in
the CNS was derived from a single gene.
However, in 2003, Walther and colleagues
discovered a new, brain-specific TPH gene
(tph2) located on the long arm of chromosome
12 (Ref. 68), a region reported to contain
susceptibility genes for bipolar disorder and
major depressive disorder (Refs 69, 70, 71, 72).
Levels of tph2 mRNA are elevated in the dorsal
and median raphe nuclei of depressed suicide
patients (Ref. 73), and, indeed, subsequent
analysis of polymorphisms in the tph2 gene has
supported an association between tph2
genotype and affective disorders (Refs 74, 75).
TPH expression is limited to a few specialised
tissues: raphe neurons (Ref. 76), pinealocytes
(Ref. 76), mast cells (Ref. 77), mononuclear
leukocytes (Ref. 78), intestinal enterochromaffin
cells (Ref. 79) and bronchopulmonary
neuroendocrine epithelial cells (Refs 80, 81).
Tryptophan hydroxylase 1 (TPH1) is highly
expressed in the pineal and peripheral tissues,
while TPH2 is highly expressed in the brain
(Refs 68, 82). Transcripts of tph1 and tph2 have
been colocalised in multiple brain regions in
post mortem human brain using quantitative
real-time PCR, with a ratio favouring tph2
mRNA expression in the primary site of
serotonin synthesis, the raphe nuclei (Ref. 83).
TPH1 and TPH2 are tetrameric holoenzymes
that catalyse the hydroxylation of tryptophan
to form 5-hydroxytryptophan (5-HTP), which
is then readily converted to serotonin (5-HT) by
aromatic amino acid decarboxylase (AADC; EC
4.1.1.28). Both TPH1 and TPH2 utilise molecular
oxygen and the cofactor tetrahydrobiopterin to
convert tryptophan to 5-HTP. The Km value for
tryptophan is reported to be 10–20 mM for TPH1
and 40–50 mM for TPH2 (Refs 84, 85). As
tryptophan concentrations in the brain range
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from 10 to 30 mM (Ref. 86) and are reportedly as
low as 2 mM in CSF (Ref. 87), these Km values are
consistent with findings that brain TPH is
unsaturated under baseline conditions (Refs 88,
89, 90). It follows, therefore, that tryptophan
loading results in increases in serotonin and
5-HIAA levels in the brain (Refs 91, 92).
The activity of TPH can be modified by
several factors. Stress-induced increases in TPH
activity have been correlated with increased
serotonin release in forebrain serotonergic
projection regions as well as locally within
the midbrain raphe nuclei (Ref. 93). TPH2
is regulated by action-potential- and Ca2þ-
dependent phosphorylation (Refs 85, 94) and
by an activating protein, 14-3-3, which binds
to the phosphorylated enzyme, preventing
dephosphosphorylation and deactivation
(Ref. 95).
It is not possible to review here the medical
implications of tryptophan metabolism in the
CNS related to serotonergic neurotransmission,
but serotonin has been implicated in many
physiological and behavioural responses, as
well as stress-related neuropsychiatric disorders
including anxiety and major depression
(Ref. 96). Stress, stress-related hormones and
stress-related neuropeptides have effects on
tryptophan availability for uptake into the
brain, on the rate of tryptophan uptake in brain
synaptosomal preparations, on serotonin
synthesis, release and metabolism, and on
postsynaptic signalling mechanisms. These
complex relationships are beyond the scope of
this article but are detailed in several excellent
reviews (Refs 97, 98, 99). Evidence supporting a
role for serotonin in depression includes: (1)
lowered CSF and brain concentrations of the
serotonin catabolite 5-HIAA in depressed
patients and particularly in depressive suicides
(Ref. 100); (2) increased susceptibility to
depression associated with polymorphisms in
the serotonin transporter (Ref. 101); (3)
elevation of chronic serotonergic function with
clinically effective antidepressants (Ref. 102);
and (4) precipitation of decreased mood or
depressive relapse caused by depletion of
tryptophan (Ref. 103).
Kynurenine biosynthesis and metabolism
In addition to the ubiquitous use of tryptophan
for protein synthesis and its role in serotonin
metabolism in the CNS, tryptophan is also a
precursor for the kynurenine pathway of
metabolism in astrocytes, infiltrating
macrophages, microglia and dendritic cells
(Fig. 3). The first step in the synthesis of
kynurenines is the oxidative opening of the
indole ring of tryptophan, and two different
haem-dependent enzymes can catalyse this
reaction. The first, tryptophan 2,3-dioxygenase
(TDO; tryptophan pyrrolase; EC 1.13.11.11) is
almost entirely localised to hepatic cells and
regulates homeostatic plasma tryptophan
concentrations. The second, IDO (EC 1.13.11.17),
is found largely in macrophages in the
periphery but is also expressed in the CNS by
astrocytes, infiltrating macrophages, microglia
and dendritic cells. The expression of IDO is
upregulated in response to infection and tissue
inflammation (Ref. 104). Neuroactive kynurenine
metabolites include the free-radical generators
3-hydroxykynurenine and 3-hydroxyanthranilic
acid (Refs 105, 106), the excitotoxic NMDA
receptor agonist and free-radical generator
quinolinic acid (Ref. 107), and the
neuroprotective NMDA and a7 nicotinic
acetylcholine receptor antagonist kynurenic acid
(Refs 108, 109). Other products of the
kynurenine pathway of tryptophan metabolism
also may have important physiological
functions; for example, picolinic acid appears to
play an important role in modulation of immune
function (Ref. 110). The expression of specific
enzymes varies across different brain regions,
and species and age differences have been noted
in the activity of specific enzymes within the
kynurenine pathway of tryptophan metabolism
(and therefore may result in differences in the
amounts of specific metabolites produced) (Refs
111, 112).
Given that the kynurenine pathway produces
both neurotoxic (e.g. quinolinic acid) and
neuroprotective (e.g. kynurenic acid)
metabolites, it is necessary to consider the ratio
of these products when attempting to correlate
metabolite concentrations with neural actions
and the pathology of neurodegenerative disease
(Ref. 106).
Tryptophan 2,3-dioxygenase
TDO is the rate-limiting enzyme in the
kynurenine pathway of tryptophan metabolism
in the periphery (Ref. 104), catalysing the
oxidative cleavage of tryptophan and regulating
homeostatic plasma tryptophan concentrations.
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The tetrameric holoenzyme contains two haem
units per tetramer, is iron- and copper-
dependent, and utilises molecular oxygen in the
catalytic cycle (Ref. 104). TDO expression can be
induced or its activity can be increased by
tryptophan and some of its analogues
(including a-methyltryptophan) via actions at a
distinct allosteric activation site (separate from
the active site for substrate binding) (Ref. 113);
consequently, tryptophan loading can increase
activity four- to tenfold within a period of
several hours (Ref. 114). Although multiple
tryptophan analogues can activate TDO, the
only substrate is tryptophan. TDO is
competitively inhibited by indoleamines
[including tryptamine, 5-HTP and melatonin
(Ref. 104)] and is subject to end-product
inhibition by the reduced form of nicotinamide-
adenine dinucleotide phosphate and other
nicotinamide analogues (Ref. 114).
It has been estimated that in peripheral tissue,
only 1% of dietary tryptophan not utilised for
protein synthesis is converted to serotonin,
while greater than 95% is metabolised via the
kynurenine pathway (Ref. 104). Not surprisingly,
plasma free tryptophan concentrations can
be influenced by the activity of hepatic
TDO (Ref. 115). Although the major site of
expression of TDO is the liver, studies using
reverse transcriptase PCR (RT-PCR) and
immunohistochemical techniques have
described TDO mRNA and protein expression
in astrocytes within the human frontal cortex
(Ref. 116), and recent studies suggest that the
enzyme and its activity are upregulated in the
anterior cingulate cortex of patients with
schizophrenia and bipolar disorder (Ref. 117).
Although it now seems clear that peripheral
TDO activity is inversely related to brain
tryptophan concentrations (Ref. 118) and that
brain tryptophan concentrations can be
dramatically increased by inhibiting TDO
activity (Ref. 119), it remains unclear how
important moderate changes in peripheral
tryptophan concentrations are in the aetiology
and pathophysiology of major depression
or other stress-related neuropsychiatric
disorders. It is clear, however, that TDO
expression and activity can be increased by
stress-related glucocorticoid hormones via
actions at both transcriptional and translational
levels (Refs 120, 121). In addition, several
antidepressant drugs including imipramine,
tranylcypramine (Ref. 122), lofepramine
(Ref. 123), desmethylimipramine (Ref. 123),
paroxetine (Ref. 124), fluoxetine (Refs 125, 126)
and others (Ref. 127) have been shown to
inhibit TDO activity – effects that are likely
to increase plasma and brain tryptophan
concentrations and to increase the rate of
serotonin biosynthesis in the brain (Ref. 128). A
full understanding of tryptophan metabolism in
the CNS during health and disease states will
require an integrative approach that also
considers the expression and activity of
peripheral, and potentially brain, TDO.
Indoleamine 2,3-dioxygenase
IDO, like TDO, catalyses the oxidative cleavage
of tryptophan. While TDO expression is largely
restricted to hepatocytes, IDO is widely
distributed in mammalian peripheral tissues as
well as within glial and immune cells in the
CNS (Ref. 104). Like TDO, IDO is a haem-
containing glycoprotein, but it functions as a
monomer (Ref. 104). IDO utilises superoxide as
well as molecular oxygen in the catalytic
process of the enzyme (Ref. 129) and is thought
to use dihydroflavin mononucleotide (FMNH2)
and tetrahydrobiopterin as cofactors (Ref. 130),
but binding sites have not been identified
(Ref. 104). By contrast with TDO, IDO has a
broad substrate specificity and will accept
several different indoleamines including D- and
L-tryptophan, tryptamine, 5-HTP, serotonin and
melatonin (see section on kynuramine
biosynthesis and metabolism, below; Ref. 131).
Furthermore, unlike TDO, IDO is not induced
by glucocorticoid hormones and contains no
allosteric activating site for tryptophan or
tryptophan analogues (Ref. 104). IDO is,
however, activated by interferon g (IFN-g),
which is released during immunological stress
(Refs 132, 133).
Because IDO is widely distributed in different
cell types in brain and peripheral tissues,
tryptophan metabolism via IDO activity is
likely to have many different functions,
dependent on the tissue type, cell type and
physiological context. In the periphery, IDO is
expressed in macrophages and dendritic cells
(Ref. 49) but can also be induced in other
cell types, such as alveolar interstitial cells of
the lung following treatment of mice with
lipopolysaccharide (Ref. 134), or the vascular
endothelium of brain, heart, lung, spleen and
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uterus following malaria infection (Ref. 135).
Expression of IDO in the vascular endothelium
of the brain and within the brain itself under
normal or pathological conditions may have
important consequences for tryptophan
availability and might influence rates of
serotonin synthesis. IDO is distributed evenly
throughout the brain but high IDO activity has
been reported in the pineal gland and choroid
plexus (Ref. 136). There is also evidence that
IDO expression in astrocytes and infiltrating
macrophages or microglia is differentially
controlled (Ref. 137). Thus, IDO expression is
dynamically regulated in different cell types in
the periphery and in the brain.
Kynurenine metabolites
Kynurenine metabolites have been implicated
in diverse aspects of physiology and
pathophysiology (Ref. 106). For example,
induction of IDO has been found to suppress
T-cell proliferation, leading to immune
tolerance. There are currently two main working
hypotheses to explain how activation of IDO
can suppress T-cell proliferation. First, it has
been proposed that IDO-mediated depletion of
tryptophan from the local environment deprives
T cells of tryptophan needed for proliferation
(Refs 138, 139). However there is also evidence
that metabolites such as 3-hydroxykynurenine,
3-hydroxyanthranilic acid and quinolinic acid
actively suppress the proliferation of activated
T cells (Refs 140, 141, 142, 143). Indeed IDO can
mediate suppression of T-cell proliferation even
when tryptophan levels remain high or are
deliberately supplemented (Ref. 143). These two
hypotheses for the mechanisms of action of
IDO-induced immunosuppression are not
mutually exclusive and suggest IDO facilitates
tolerance to antigens, with implications for
protection of the fetus during pregnancy
(Ref. 144), tumour immune escape in cancer
therapy (Ref. 145), and allograft survival
(Ref. 141). The current understanding of the
respective contributions of local tryptophan
depletion and tryptophan utilisation in the
functions of IDO in the immune response
has been addressed in comprehensive reviews
(Refs 142, 146, 147). In addition, recent interest
has focused on the possibility that IDO, through
its effects on tryptophan metabolism via the
kynurenine pathway, might play a role in the
aetiology and pathophysiology of depression
(Ref. 148).
The main neuroactive kynurenine metabolites
are quinolinic acid, 3-hydroxykynurenine,
3-hydroxyanthranilic acid and kynurenic acid
(Ref. 106).
Quinolinic acid
Quinolinic acid can selectively activate the
NMDA-sensitive subpopulation of glutamate
receptors (Ref. 107), allowing it not only to
excite neurons but also to cause neuronal
damage resulting from overstimulation of the
receptor (Ref. 149) – a process that is
exacerbated by activation of metabotropic
glutamate receptors by endogenous glutamate
(Ref. 150). A large volume of evidence has
accumulated suggesting that quinolinic acid
might play an important pathological role in
several CNS disorders, such as acquired
immunodeficiency syndrome (AIDS) dementia
complex (Ref. 151), Huntington’s disease
(Ref. 152) and Alzheimer’s disease (Refs 153,
154, 155), while IDO activity is increased in a
variety of other neuroinflammatory diseases
including hepatic encephalopathy, septicaemia
and neurovirological disorders (Ref. 156; for
reviews, see Refs 157, 158). However, quinolinic
acid is selectively stored in macrophages
and may be a substrate for extrahepatic
nicotinamide adenosine dinucleotide (NADþ)
synthesis for alleviation of neuronal damage
caused during an immune response. NADþ is
required in a poly(ADP-ribose) polymerisation
reaction used to repair DNA damage incurred
by reactive oxygen and nitrogen species during
an immune response (Ref. 137). Indeed, IFN-g,
released during immune stress, induces NADþ
synthesis in macrophages with quinolinic acid
as a substrate (Ref. 159).
3-Hydroxykynurenine
3-Hydroxykynurenine (and its metabolite
3-hydroxyanthranilic acid) are less potent
toxins than quinolinic acid and the neuronal
damage produced appears to be mediated
by free radicals and not through glutamate
receptors (Ref. 160). Elevated levels of
3-hydroxykynurenine have been reported in
patients with Huntington’s disease (Ref. 161),
and in cell culture 3-hydroxykynurenine can
induce neuronal cell death, particularly in
cortical and striatal neurons (Ref. 162).
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Kynurenic acid
Kynurenic acid acts as an antagonist at NMDA
receptors and has been found to be particularly
active as an antagonist at an allosteric site on
the NMDA receptor for which glycine or serine
appears to be the endogenous, essential co-
agonist (Ref. 163). The NMDA antagonist
activity of kynurenic acid is probably
responsible for its ability to prevent brain
damage following ischaemia in rats (Ref. 164).
These properties of kynurenic acid have led to
the development of several compounds with
potential therapeutic value in the treatment of
stroke, epilepsy and neurodegenerative
disorders (Refs 49, 106, 165).
Melatonin biosynthesis and metabolism
Melatonin is synthesised within the pineal gland
and to a lesser extent in the retina (Ref. 166).
Melatonin synthesis in the pineal gland varies
dramatically in a circadian fashion (with high
levels of synthesis and secretion during the dark
phase of the circadian cycle) and is thought to be
an important neuroendocrine signal conveying
circadian and seasonal information to multiple
organ systems, including the brain. Figure 4
illustrates the biosynthetic pathway for the
synthesis of melatonin from tryptophan. The
rate-limiting step in the synthesis of melatonin
from serotonin is catalysed by the cytoplasmic
enzyme serotonin N-acetyltransferase
(arylalkylamine N-acetyltransferase, AANAT;
EC 2.3.1.5), an enzyme that displays a circadian
rhythm in activity, with higher activity during
the dark phase of the circadian cycle (Refs 167,
168). The final step in the biosynthesis of
melatonin is catalysed by hydroxyindole-O-
methyltransferase (HIOMT), which does
not show circadian variations in activity
(Ref. 168). Thus, the rhythm in serotonin
N-acetyltransferase activity regulates the
circadian rhythm of melatonin synthesis.
Melatonin regulates many physiological and
behavioural responses including sexual
maturation and reproductive behaviour,
thermoregulation, sleep patterns, metabolism,
haematopoiesis, immune responses, and
reduction of oxidative stress (Refs 169, 170).
Serotonin N-acetyltransferase
Serotonin N-acetyltransferase, the penultimate
enzyme in melatonin synthesis, belongs to the
Tryptophan metabolism in
pinealocytes
Expert Reviews in Molecular Medicine
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Trp
Extracellular fluid
Pinealocyte
5-HTP
5-HT
Trp
transporter
Tryptophan hydroxylase 1
(O2, BH4)
Aromatic L-amino acid
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Figure 4. Tryptophan metabolism in pinealocytes.
Tryptophan (Trp) in the extracellular fluid is
transported into the pinealocyte by a high-affinity
tryptophan transporter. In the pinealocyte,
tryptophan hydroxylase 1, using molecular oxygen
(O2) and the cofactor tetrahydrobiopterin (BH4),
catalyses the hydroxylation of tryptophan to
5-hydroxytryptophan (5-HTP), which is rapidly
converted to 5-hydroxytryptamine (5-HT, serotonin)
by aromatic L-amino acid decarboxylase, using
pyridoxal-50-phosphate (P5P) as cofactor. Serotonin
N-acetyltransferase catalyses the conversion of
serotonin to N-acetylserotonin, which is rapidly
converted to melatonin by hydroxyindole-O-
methyltransferase. The activity of serotonin
N-acetyltransferase is responsible for the circadian
fluctuations of melatonin synthesis in the pineal
gland. For chemical structures of key metabolites,
see Ref. 106.
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GCN5-related N-acetyltransferase superfamily
of acetyltransferases (Ref. 171). The mechanisms
underlying the rhythmic expression of
serotonin N-acetyltransferase have been
extensively studied (Refs 172, 173). These
studies highlight an important role for the
adrenergic induction of the cyclic AMP
pathway in regulation of enzyme activity, as
well as post-translational control of enzyme
activity as proteolysis is responsible for the
rapid decrease in serotonin N-acetyltransferase
activity following sudden exposure to light
during the dark phase (Ref. 174). As described
above for TPH, serotonin N-acetyltransferase
binds to 14-3-3 protein in a phosphorylation-
dependent manner, which decreases the Km for
substrate binding (Ref. 175) and is believed to
protect the enzyme from proteolysis (Refs 174,
176).
The cDNA for serotonin N-acetyltransferase
has been cloned (Ref. 177). Unexpectedly, in
addition to high expression in the pineal gland
and retina, serotonin N-acetyltransferase mRNA
was found in the pituitary gland and also in
several brain regions (Ref. 177). Although the
function of serotonin N-acetyltransferase in
extra-pineal tissues including the brain is not
certain, recent studies have shown that the
expression of serotonin N-acetyltransferase
mRNA in brain can be upregulated by chronic
cocaine or antidepressant treatment (Ref. 178).
Kynuramine (kynurenamine) biosynthesis
and metabolism
Although melatonin itself is known to signal
within the CNS via actions on high-affinity
melatonin 1 (MT1) and melatonin 2 (MT2)
G-protein-coupled receptors (Ref. 179), it has
also been proposed that kynuramine
metabolites of melatonin [also called
kynurenamines – not to be confused with
kynurenines (Ref. 180)], may also have
important physiological functions. Kynuramine
metabolites of melatonin include N-formyl-N-
acetyl-5-methoxy kynuramine (AFMK; N-
formyl-N-acetyl-5-methoxy kynurenamine)
formed in the brain by the action of IDO, the
same enzyme responsible for the conversion of
tryptophan to formylkynurenine in the
kynurenine pathway of tryptophan metabolism
(Ref. 104), and N-acetyl-5-methoxy kynuramine
(AMK; N-acetyl-5-methoxy kynurenamine)
formed in the brain by the action of
formamidase (EC 3.5.1.49), the same enzyme
responsible for conversion of formylkynurenine
to kynurenine in the kynurenine pathway of
tryptophan metabolism (Ref. 104). Peripheral
administration of melatonin leads to increases
in AFMK concentrations in retina, plasma and
CSF in rats (Ref. 181). Proposed functions of
AMK and AFMK include inhibition of
prostaglandin synthesis (Ref. 182), regulation of
cytokine release from neutrophils (Ref. 183),
and scavenging of free radicals (Ref. 184).
Physiological and behavioural effects of other
kynuramines [potentially derived from
kynurenine, tryptamine (see below) or serotonin
(Refs 106, 180)], including kynuramine and
5-hydroxykynuramine, have been studied
(Refs 180, 185) but little is known about the
physiological or behavioural significance of
these endogenous kynuramines. The finding
that concentrations of the melatonin metabolite
AFMK are elevated in the CSF of viral
meningitis patients and are correlated with pro-
inflammatory cytokines has led to the
hypothesis that inflammation favours the
formation of AFMK and that this compound
has immunomodulatory activity in vivo
(Ref. 186).
Trace amine biosynthesis and
metabolism
Trace amines are endogenous amine
compounds structurally related to the classical
monoamine neurotransmitters. Trace amines
include b-phenylethylamine, p-tyramine,
m-tyramine, m-octopamine, p-octopamine and
tryptamine (Refs 187, 188, 189). Although the
presence of trace amines in the vertebrate CNS
was well documented during the 1970s and
1980s (for references, see Ref. 188) they were
often considered metabolic by-products. The
recent identification of a novel family of
G-protein-coupled receptors that includes
members with high affinity for specific trace
amines (Ref. 189) has led to a resurgence of
interest in these compounds and the possibility
that they might play important physiological or
pathophysiological roles (Ref. 188).
For the purposes of this review, we focus
on the decarboxylation of tryptophan by
AADC to form tryptamine (Ref. 189). Tryptamine
in turn is converted to the secondary amine
N-methyltryptamine, or inactivated by
monoamine oxidase, which converts tryptamine
expert reviews
http://www.expertreviews.org/ in molecular medicine
14
Accession information: DOI: 10.1017/S1462399406000068; Vol. 8; Issue 20; August 2006
&2006 Cambridge University Press
Tr
yp
to
ph
an
m
et
ab
ol
is
m
in
th
e
ce
nt
ra
ln
er
vo
us
sy
st
em
:m
ed
ic
al
im
pl
ic
at
io
ns
to the acid metabolite indoleacetic acid (Fig. 5).
Immunohistochemical studies suggest that
tryptamine-containing cell bodies are present
around the aminergic cell groups within the
interpeduncular nucleus, substantia nigra, and
rostral dorsal raphe nucleus (Ref. 190). This
distribution overlaps with the distribution of the
‘D4’ group of AADC-only neurons in the rat
brain (Ref. 191) – neurons containing AADC that
are neither catecholaminergic nor serotonergic
and therefore are ideal candidates for neurons
that synthesise trace amines. Tryptamine has a
unique distribution of binding sites in brain
(Ref. 192) and activates the recently cloned and
characterised trace-amine-associated receptors 1
(TAAR1) and 4 (TAAR4), albeit at micromolar
concentrations. Electrophysiological studies have
demonstrated that tryptamine modulates cortical
serotonergic neurotransmission (Ref. 193), and
a general role of trace amines in modulation
of monoaminergic neurotransmission has
been proposed (Ref. 188). Although it has
been hypothesised that trace amines may play
an important role in major depression,
schizophrenia or other neuropsychiatric
disorders (Refs 189, 194), full characterisation
of the physiological or pathophysiological
functions of tryptamine and other trace amines
awaits identification of high-affinity receptors
and development of selective antagonists.
Summary
Tryptophan is an essential amino acid that
is ingested as part of the diet. Diverse
mechanisms contribute to the regulation of
tryptophan availability within the CNS. An
important factor is the rate of tryptophan
transport across the BBB, determined by plasma
concentrations of free tryptophan and the ratio
of tryptophan to other LNAAs, which in turn
are determined by (1) peripheral TDO activity,
(2) regulation of the affinity of tryptophan
for circulating albumin (for example by
NEFAs or by interactions between the
tryptophan–albumin complex and the
glycocalyx of the endothelial cell membrane),
and (3) sympathetic nervous system activity.
Tryptophan in the extracellular fluid or CSF in
the CNS is available for cellular uptake by
multiple cell types with unique metabolic
demands for tryptophan, including serotonergic
neurons, mast cells, astrocytes, microglia,
macrophages and dendritic cells, emphasising
the need to understand the molecular
mechanisms underlying cellular uptake of
tryptophan by different cell types. The diversity
of metabolites of tryptophan in the CNS,
including serotonin, products of the kynurenine
Tryptophan metabolism in
tryptaminergic neurons
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Figure 5. Hypothetical model of tryptophan
metabolism in tryptaminergic neurons. Tryptophan
(Trp) in the extracellular fluid is transported into the
tryptaminergic neuron by a high-affinity neuronal
tryptophan transporter. In tryptaminergic cells,
aromatic L-amino acid decarboxylase (AADC)
catalyses the decarboxylation of tryptophan to form
tryptamine, in the absence of either tryptophan
hydroxylase or tyrosine hydroxylase. This reaction
may occur in ‘AADC-only’ neurons, also called ‘D’
neurons, that have been described in specific cell
clusters in brain. Tryptamine is metabolised by
monoamine oxidase and indole-3-acetaldehyde
oxidase to the acid metabolite indole-3-acetic acid,
which is excreted from the cell. For chemical
structures of keymetabolites, see Ref. 106.
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Clinical conditions associated with altered tryptophan metabolism in the
central nervous system
Expert Reviews in Molecular Medicine C 2006 Cambridge University Press
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Neurodegenerative disorders
(e.g. AIDS dementia complex)
↑Brain IDO
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↑Hepatic TDO
Peripheral immune activation/
stress/glucocorticoids
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Figure 6. Clinical conditions associated with altered tryptophan metabolism in the central nervous
system. Diverse neurological and neuropsychiatric conditions have been associated with altered tryptophan
metabolism in the central nervous system (CNS) (for reviews see Refs 49, 105, 106, 157, 158, 200, 201).
Neurodegenerative disorders involving central immune activation, including infections of the CNS (e.g. AIDS
dementia complex, meningitis), autoimmune disorders (e.g. multiple sclerosis, systemic lupus erythematosus),
and other inflammatory conditions (e.g. Lyme disease, malaria), are associated with activation of brain
indoleamine 2,3-dioxygenase (IDO) and increases in brain concentrations of kynurenines as secondary
mediators of dysfunctional states. Increased brain IDO activity is due to actions of interferon g (IFN-g), acting in
concert with other immune signalling molecules including interleukin 1b (IL-1b) and tumour necrosis factor a
(TNF-a). By contrast, in stress-related neuropsychiatric disorders, glucocorticoid hormones increase
transcription of tryptophan 2,3-dioxygenase (TDO) and peripheral degradation of tryptophan via the kynurenine
pathway, limiting tryptophan availability for serotonin synthesis. Complex interactions between kynurenine and
serotonin pathways of tryptophan metabolism are likely in many conditions. For example, L-kynurenine
competes with tryptophan and other large neutral amino acids for transport across the blood–brain barrier
(Ref. 202). Increased L-kynurenine from peripheral sources may contribute to the formation of brain quinolinic
acid in the presence of central immune activation (left). In contrast, increased L-kynurenine from peripheral
sources, by competing with tryptophan for uptake into the brain, may further limit tryptophan availability for
serotonin synthesis in neuropsychiatric disorders (right). Consequently, concurrent activation of IDO and TDO
by peripheral immune activation and stress, respectively, may have additive effects, decreasing tryptophan
availability, serotonin synthesis, and serotonergic neurotransmission, as has been described for example in
patients with major depression (see text). This effect may be reversed by antidepressants that inhibit TDO
activity and serotonin reuptake, increasing tryptophan availability and serotonergic neurotransmission (see
text), while subsequent acute tryptophan depletion results in a transient recurrence of depressive symptoms in
patients who had responded to treatment with selective serotonin reuptake inhibitors (Ref. 103). It remains
uncertain if the effects of acute tryptophan depletion in neuropsychiatric disorders are a result of changes in
serotonergic neurotransmission, changes in signalling by other tryptophan metabolites, or both.
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pathway of tryptophan metabolism (including
3-hydroxykynurenine, 3-hydroxyanthranilic
acid, quinolinic acid and kynurenic acid), the
neurohormone melatonin, several neuroactive
kynuramine metabolites of melatonin, and the
trace amine tryptamine, points towards a need
for integrative approaches to understand the
functional consequences of tryptophan
metabolism in the CNS.
Clinical implications and future directions
Tryptophan depletion has been shown to result
in a rapid induction of depressive symptoms in
patients that have been treated with selective
serotonin-reuptake inhibitors (Refs 195, 196).
Although these results and others (Ref. 103)
have been interpreted as evidence for a role for
serotonergic systems in the regulation of mood,
tryptophan depletion has the potential to
simultaneously alter tryptophan metabolism
within the serotonin, kynurenine, melatonin
and trace amine pathways of metabolism. The
clinical significance of selectively altering
tryptophan metabolism within each of these
metabolic pathways or shuttling of tryptophan
into the kynurenic acid versus the quinolinic
acid pathway of metabolism (e.g. by inhibiting
kynureninase and kynurenine 3-hydroxylase),
effectively altering the ratio between
neuroprotective and neurotoxic kynurenine
metabolites, has immense and obvious clinical
significance (Ref. 106) (Fig. 6). Given the
diversity of bioactive metabolites of tryptophan
derived from different metabolic pathways in
the CNS, caution should be exercised in the use
of tryptophan loading, particularly during
inflammatory disease when IDO expression is
often upregulated, or in subjects in whom the
induction of oxidative stress would be contra-
indicated (Ref. 197).
Evidence is accumulating that there is
anatomical, physiological and functional
diversity among subpopulations of serotonergic
neurons (Refs 47, 198). It will be important in
future studies to determine the cellular
mechanisms regulating tryptophan uptake into
specific cellular compartments, including not
only subpopulations of serotonergic neurons
but also astrocytes, infiltrating macrophages,
microglia, dendritic cells and mast cells.
Identification and characterisation of the
molecular mechanisms underlying high-affinity
tryptophan uptake into different cell types
within the CNS might lead to novel therapeutic
strategies based on specific regulation of
different metabolic pathways for tryptophan. It
will also be important to determine how stress
interacts with tryptophan metabolism at the
level of cellular uptake as well as intraneuronal
trafficking and compartmentalisation of
tryptophan and enzyme activity.
Further studies of associations between
genetic polymorphisms in genes regulating
different aspects of tryptophan metabolism –
for example, TPH2, TDO, and ABCG transport
genes – and specific neuropsychiatric disorders
should lead to important advances in our
understanding of the medical implications of
altered tryptophan metabolism in the CNS.
Advances in imaging technology and the
application of this technology to preclinical
models should aid in determining the
distribution of specific receptors for neuroactive
tryptophan metabolites, while development of
specific receptor antagonists will be critical in
defining their function. Given the diversity of
neuroactive signalling molecules derived from
tryptophan, and the broad substrate specificity
of IDO, integrative approaches will be required
to understand interactions among different
pathways of tryptophan metabolism in health
and disease states.
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Note added in proof
Wang and colleagues have reported that
kynurenic acid is a ligand for the orphan
G-protein-coupled receptor GPR35, adding
another dimension to the complexity of signalling
mechanisms for metabolic intermediates of the
kynurenine pathway (Ref. 203).
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Further reading, resources and contacts
Resources
Information about tryptophan and tryptophan metabolites:
http://en.wikipedia.org/wiki/5-HTP
http://en.wikipedia.org/wiki/Melatonin
http://en.wikipedia.org/wiki/Niacin
http://en.wikipedia.org/wiki/Serotonin
http://en.wikipedia.org/wiki/Tryptamines
http://en.wikipedia.org/wiki/Tryptophan
Health information on tryptophan from the United States National Library of Medicine and the National
Institutes of Health:
http://www.nlm.nih.gov/medlineplus/druginfo/uspdi/500179.html
OMIM (Online Mendelian Inheritance in Man) database of human genes and genetic disorders:
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?CMD ¼ search&DB ¼ omim
Reference pathway for tryptophan metabolism from Kyoto Encyclopedia of Genes and Genomes:
http://www.genome.jp/kegg/pathway/map/map00380.html
Reference pathway for nicotinic acid and nicotinamide metabolism from Kyoto Encyclopedia of Genes and
Genomes:
http://www.genome.jp/kegg/pathway/map/map00760.html
United States National Library of Medicine and the National Institutes of Health including access to
PubMed (biomedical journal literature):
http://www.nlm.nih.gov/
ExPASy Proteomics Server. The ExPASy (Expert Protein Analysis System) proteomics server of the Swiss
Institute of Bioinformatics (SIB) is dedicated to the analysis of protein sequences and structures, and
includes an enzyme nomenclature database with a search engine for EC (Enzyme Commission) numbers:
http://ca.expasy.org/
Related tools and databases:
Biochemical Pathways – interactive access to Roche Applied Science ‘Biochemical Pathways’:
http://www.expasy.org/tools/pathways/
BRENDA – comprehensive enzyme information system:
http://www.brenda.uni-koeln.de/
KEGG – Kyoto Encyclopedia of Genes and Genomes:
http://www.genome.ad.jp/kegg/
MetaCyc – Metabolic Encyclopedia of enzymes and metabolic pathways:
http://www.metacyc.org/
IUBMB enzyme nomenclature:
http://www.chem.qmul.ac.uk/iubmb/enzyme/
Enzymes and Metabolic Pathways (EMP) database:
http://www.empproject.com/
Authors’ institute URLs: http://www.bris.ac.uk/Depts/URCN/labs/lowry.html;
http://www.bristol.ac.uk/neuroscience
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Features associated with this article
Figures
Figure 1. Overview of tryptophan metabolism in the central nervous system.
Figure 2. Tryptophan metabolism in serotonergic neurons.
Figure 3. Tryptophan metabolism in astrocytes, infiltrating macrophages, microglial cells and dendritic cells
in the central nervous system.
Figure 4. Tryptophan metabolism in pinealocytes.
Figure 5. Hypothetical model of tryptophan metabolism in tryptaminergic neurons.
Figure 6. Clinical conditions associated with altered tryptophan metabolism in the central nervous system.
Table
Table 1. Tryptophan uptake systems in pineal and central nervous system tissues.
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